Search / 156 results found

from
to
  • Updated

TUESDAY, Jan. 18, 2022 (HealthDay News) -- Two sets of guidelines have been developed: one for the diagnosis and management of acute left-sided colonic diverticulitis and a second for the role of colonoscopy for diagnostic evaluation and interventions to prevent recurrence of acute left-sided colonic diverticulitis; the guidelines were published online Jan. 18 in the Annals of Internal Medicine.

  • Updated

TUESDAY, Jan. 18, 2022 (HealthDay News) -- In a clinical practice guideline issued by the American Society for Radiation Oncology and published in the January issue of Practical Radiation Oncology, recommendations are presented for the use of external beam radiation therapy (EBRT) for hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (IHC).

  • Updated

TUESDAY, Jan. 18, 2022 (HealthDay News) -- Among patients with bone and brain metastases who died within 90 days of radiotherapy receipt, 21.6 percent received guideline-nonconcordant therapy, according to a research letter published online Jan. 14 in JAMA Health Forum.

  • Updated

TUESDAY, Jan. 18, 2022 (HealthDay News) -- Patients who have gastric bypass may be slightly more likely to remain free of obesity-related medications versus those undergoing sleeve gastrectomy, according to a study published online Jan. 12 in JAMA Surgery.

  • Updated

TUESDAY, Jan. 18, 2022 (HealthDay News) -- Two years into the pandemic, coronavirus treatments like monoclonal antibodies and antiviral pills have been approved to treat COVID-19, but it's hard to keep track of which ones still work, experts say.

  • Updated

FRIDAY, Jan. 14, 2022 (HealthDay News) -- The nomination of former U.S. Food and Drug Administration head Robert Califf, M.D., to again lead the agency now heads to the full Senate for a vote, after a Senate committee on Thursday voted 13-8 for approval.

  • Updated

FRIDAY, Jan. 14, 2022 (HealthDay News) -- The Janus kinase (JAK) inhibitor baricitinib is strongly recommended for patients with severe or critical COVID-19, and sotrovimab is conditionally recommended for nonsevere COVID-19, according to the updated World Health Organization living guideline on drugs for COVID-19, published online Jan. 13 in The BMJ.